WEST PHARMACEUTICAL SERVICES INC

WST

$19.39B

Large Cap

NASDAQBiotechnology🇺🇸North America10.6K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

Fish Oil Phase 2 Results Expected

February 2026~Fish Oil120

Primary completion for Fish Oil trial (NCT06279793) in Intensive Care Unit

Source

Phase 2

RVU120 (SEL120) Phase 2 Results Expected

May 2026~RVU120 (SEL120)41

Primary completion for RVU120 (SEL120) trial (NCT06243458) in Low Risk Myelodysplastic Syndromes

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Morphine Sulfate

Phase 3

Pain, Postoperative

Phenobarbital

Phase 3

Epilepsy

Imetelstat sodium

Phase 2

Myelodysplastic Syndromes

Fish Oil

Phase 2

Intensive Care Unit

RVU120 (SEL120)

Phase 2

Low Risk Myelodysplastic Syndromes

Drug Name	Phase	Indication	Designations
Morphine Sulfate	Phase 3	Pain, Postoperative	-
Phenobarbital	Phase 3	Epilepsy	-
Imetelstat sodium	Phase 2	Myelodysplastic Syndromes	-
Fish Oil	Phase 2	Intensive Care Unit	-
RVU120 (SEL120)	Phase 2	Low Risk Myelodysplastic Syndromes	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

WST News